News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Sanofi-Aventis (France) Pulls Obesity Drug Application in U.S.
June 29, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Reuters) - Sanofi-Aventis said on Friday it was withdrawing its application to sell obesity drug rimonabant -- its biggest new drug hope -- in the United States.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Sanofi
MORE ON THIS TOPIC
Podcast
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
November 11, 2026
·
2 min read
·
Jef Akst
Sickle cell disease
Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success
November 10, 2026
·
3 min read
·
Heather McKenzie
Approvals
Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival
November 10, 2026
·
2 min read
·
Gabrielle Masson
GLP-1
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
November 10, 2026
·
2 min read
·
Nick Paul Taylor